# An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

> **NCT00485303** · PHASE2 · COMPLETED · sponsor: **Cougar Biotechnology, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Prostatic Neoplasms
- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00485303
- **Lead sponsor:** Cougar Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485303, "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00485303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*